Clinical trials
Solid Tumor clinical trials
Below are recruiting solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,667 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07004296RecruitingPhase 1
Study of HDM2005 for advanced solid tumors
This trial tests a new drug, HDM2005, in people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective for tumors that show a specific marker called ROR1.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06993870RecruitingPhase 1
First-in-human study of HBT-708 for advanced solid tumors
This trial tests a new drug called HBT-708 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how the body handles it.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Newport Beach, CaliforniaAges 18 years+ - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06992713RecruitingPhase 1
Study of H1710 for advanced solid tumors
This trial tests a new drug called H1710 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if H1710 is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT06990698RecruitingPhase 1
Testing FP008 in advanced solid tumors
This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.
Guangzhou, GuangdongAges 18 years+ - NCT06985368RecruitingPhase 1
Testing SIBP-A18 for advanced solid tumors
This trial tests a new drug, SIBP-A18, for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers that have a protein called CLDN18.2.
Beijing, Beijing MunicipalityAges 18–75 - NCT06983743RecruitingPhase 1
ERAS-0015 for Advanced Solid Tumors With RAS Mutations
This trial tests an experimental oral drug called ERAS-0015 for people with advanced solid tumors that have certain genetic changes (RAS mutations). It may be an option if you have no standard treatments left or cannot take them.
Santa Rosa, CaliforniaAges 18–99 - NCT06953323RecruitingPhase 1/Phase 2
Study of WJB001 combination for advanced solid tumors
This trial tests a new combination drug for people with advanced solid tumors, especially certain gynecologic cancers, that have not responded to standard treatments. The treatment aims to target a specific genetic marker (CCNE1) found in the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06959706RecruitingPhase 1
Study of TGW101 for advanced solid tumors
This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT06936735RecruitingPhase 1
HS-20108 for advanced solid tumors (phase 1)
This phase 1 study tests an investigational drug called HS-20108 in people with advanced solid tumors. It aims to find a safe dose and see how well the drug works against cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06938880RecruitingPhase 1/Phase 2
ZGGS18 plus ZG005 for advanced solid tumors
This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06929663RecruitingPhase 1
Study of AK146D1 for advanced solid tumors
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
Sydney, New South WalesAges 18–75 - NCT06927570RecruitingPhase 1
Study of HS-20122 for advanced solid tumors
This trial tests a new drug called HS-20122 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT06925581RecruitingPhase 1/Phase 2
Trial of HRS-6768 for advanced solid tumors
This trial tests a new drug called HRS-6768 for people with advanced solid tumors that have stopped responding to standard treatments or have no good options. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–80 - NCT06922357RecruitingPhase 1/Phase 2
Testing HRS-6719 for advanced solid tumors
This trial tests a new drug called HRS-6719 for people with advanced or metastatic solid tumors that have progressed after standard treatments or for which no standard treatment exists. The goal is to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06911489RecruitingPhase 1
Safety trial of a new targeted therapy for advanced solid tumors
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
ShanghaiAges 18–80 - NCT06907043RecruitingPhase 1/Phase 2
Study of PARP1 inhibitor EIK1004 for advanced solid tumors
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
Denver, ColoradoAges 18–89 - NCT06898450RecruitingPhase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18–99 - NCT06882135RecruitingPhase 1
Testing an experimental drug for advanced solid tumors
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06880549RecruitingPhase 1
mRNA cancer vaccines alone or with other drugs for solid tumors
This study tests two experimental mRNA vaccines (mRNA-4106 and mRNA-4200) given either alone or together with other cancer treatments. The goal is to see if they are safe and work against advanced or metastatic solid tumors like melanoma, lung, liver, and colon cancer. Participation requires that you have tried or refused all standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Gilbert, ArizonaAges 18 years+ - NCT06859762RecruitingPhase 1
Study of YL217 for advanced solid tumors
This study tests an experimental drug called YL217 in people with advanced solid tumors that have not responded to other treatments. The drug may work by targeting a protein on cancer cells and delivering a chemotherapy-like agent directly to the tumor, potentially slowing or stopping its growth.
Phoenix, ArizonaAges 18 years+ - NCT06826040RecruitingPhase 1
A study of SKB445 for solid tumors
This trial tests a new drug called SKB445 for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if the drug is safe and effective for these patients.
Jinan, ShandongAges 18–75
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor?
- Yes. Clin2 currently lists 1,667 recruiting solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.